Keywords: FDA, Merck & Co, Dulera, Asthma, Chagas disease, Phase II trial, Noxafil, Posaconazole

FDA approves Merck' & Co’s Dulera for asthma in patients; firm initiates Ph II trial of Chagas drug candidate

Article | 25 June 2010

Print This

US drug giant Merck & Co had two pieces of good news yesterday; it received US regulatory clearance for a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in